In the '90s, a friend of mine was in the pharma industry. During a training session, the question came up: "Is it possible to market a useless drug as a panacea?" The straightforward answer, according to the trainer, was "Yes—if the projected profits surpass the potential liability costs." All of the outcry was likely anticipated when they made that decision.